The tumor necrosis factor (TNF) superfamily member CD70 (also known as TNFSF7) has previously been identified as a biomarker and potential target for the treatment of certain malignancies.

“Because there’s a paucity of samples that are well characterized with EGFR inhibitor resistance, CD70 hasn’t been observed before,” says Heymach. CD70’s exact role is unclear, but it ...